Related Experiment Video

Updated: Jun 2, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality

Frank L Meyskens1, Eugene W Gerner

  • 1Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA. flmeyske@uci.edu

Cancer Prevention Research (Philadelphia, Pa.)
|May 6, 2011
PubMed

Insights

Synthetic lethality, a therapeutic strategy targeting cancer-driving mutations, offers new treatment avenues. This approach exploits specific genetic vulnerabilities for cancer therapy and prevention, particularly in difficult-to-treat cancers.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Carcinogenesis involves mutations that can create therapeutic vulnerabilities.
  • Synthetic lethality is a concept where combined genetic defects cause cell death.

Purpose of the Study:

  • To explore the therapeutic potential of synthetic lethality in cancer treatment.
  • To discuss the application of synthetic lethality in animal models of human cancer.
  • To review the advantages, disadvantages, and clinical challenges of synthetic lethality.

Main Methods:

  • Review of existing literature on synthetic lethality.
  • Analysis of principles and applications in yeast and cancer models.
  • Discussion of clinical implementation challenges.

Main Results:

  • Synthetic lethality offers a therapeutic window by targeting specific mutations.
  • The approach shows promise in treating and preventing cancers, especially refractory types.
  • Clinical application faces challenges that require further investigation.

Conclusions:

  • Synthetic lethality is a promising strategy for treating cancers refractory to standard therapies.
  • Further research is needed to overcome clinical implementation challenges.
  • This approach holds potential for both treatment and prevention in oncology.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.